SCHEMBL6835570

SCHEMBL6835570

O=C(O)c1ccc2c(c1)C(=O)C(Cc1ccc(F)c(F)c1)[S+]([O-])N2

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRK6 P43250 1/20 0.34
HDAC2 Q92769 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
PTGER1 P34995 1/20 0.33
ALDH1A1 P00352 1/20 0.33
TSHR P16473 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
RARB P10826 1/20 0.33
VNN1 O95497 1/20 0.33
TBXA2R P21731 1/20 0.32
PTGER4 P35408 1/20 0.32
PTGER3 P43115 1/20 0.32
PTGER2 P43116 1/20 0.32
PPARA Q07869 1/20 0.32
PRKAB2 O43741 1/20 0.32
PRKAG1 P54619 1/20 0.32
PRKAA2 P54646 1/20 0.32
PRKAA1 Q13131 1/20 0.32
PRKAG3 Q9UGI9 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6831785 0.91 KDM4E (0.36) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL6835278 0.91 KDM5A (0.35) PTGER1TSHRPTGER4PRKAB2PRKAG1
SCHEMBL6831723 0.88 ALDH1A1 (0.38) ALDH1A1TSHR
SCHEMBL6680629 0.85 KMT2A (0.40) PTGER1L3MBTL1
SCHEMBL6834783 0.85 TSHR (0.40) TSHR
SCHEMBL6835340 0.84 CNR1 (0.41) L3MBTL1PTGER4
SCHEMBL6835347 0.84 RXRA (0.40) ALDH1A1KDM4CKDM5B
SCHEMBL6831844 0.81 ALDH1A1 (0.45) HDAC2HDAC8HDAC6ALDH1A1L3MBTL1
SCHEMBL6831808 0.77 HTR7 (0.36) HDAC2HDAC8HDAC6PTGER1ALDH1A1
SCHEMBL6681850 0.76 HDAC2 (0.42) GRK6HDAC2HDAC8HDAC6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040043985-A1 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors HICKS JAMES LESTER (US) 2004-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040043985-A1 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors MMP13, MMP26, MMP9 GRK6 365/4885HDAC2 156/4885HDAC8 711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.